Naleen Raj Bhandari
Overview
Explore the profile of Naleen Raj Bhandari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liao C, Gonzalez-Ferrer C, Whipple S, Peterson P, Barker S, Bhandari N, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594790
Objectives: This study described real-world patient characteristics and outcomes among selpercatinib-treated patients in the United States, using the Flatiron Health electronic health record-derived deidentified database (FHD) for advanced/metastatic non-small cell...
2.
Bhandari N, Gilligan A, Myers J, Ale-Ali A, Smolen L
J Med Econ
. 2024 Feb;
27(1):348-358.
PMID: 38334069
Objective: To estimate the potential budget impact on US third party payers (commercial or Medicare) associated with addition of selpercatinib as a tumor-agnostic treatment for patients with Rearranged during Transfection...
3.
Hess L, Peterson P, Sugihara T, Bhandari N, Krein P, Sireci A
Cancer Treat Res Commun
. 2023 Sep;
37:100761.
PMID: 37717466
Objectives: This study compared outcomes between patients with biomarker-positive advanced/metastatic non-small cell lung cancer (a/mNSCLC) who initiated treatment with targeted therapy versus those who initiated chemotherapy-based treatment and switched to...
4.
Bhandari N, Hess L, He D, Peterson P
J Natl Compr Canc Netw
. 2023 Sep;
21(9):934-944.e1.
PMID: 37673115
Background: Little is known about the impact of up-front biomarker testing on long-term outcomes in patients with advanced or metastatic non-small cell lung cancer (a/mNSCLC). This study compared overall survival...
5.
Norton J, Khalil M, Bhandari N, Acharya M, Payakachat N, Davis R, et al.
Urol Pract
. 2023 May;
8(4):431-439.
PMID: 37145459
Introduction: Pelvic organ prolapse is a highly prevalent condition that is commonly managed with surgical intervention. Our purpose was to determine associated factors and postoperative morbidity rates of early (≤1...
6.
Hess L, Han Y, Zhu Y, Bhandari N, Sireci A
BMC Cancer
. 2023 Apr;
23(1):382.
PMID: 37101117
No abstract available.
7.
Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA
Bhandari N, Hess L, Parikh R, Sireci A, Krein P, Kaye J
Per Med
. 2023 Feb;
20(2):131-142.
PMID: 36749615
To describe real-world testing patterns for in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. The authors performed a retrospective medical...
8.
Zou D, Ye W, Hess L, Bhandari N, Ale-Ali A, Foster J, et al.
J Mol Diagn
. 2022 Jun;
24(8):901-914.
PMID: 35688357
The study evaluated the diagnostic value and cost-effectiveness of next-generation sequencing (NGS)-based testing versus various combinations of single-gene tests (SGTs) for selection of first-line treatment for patients with advanced/metastatic non-squamous...
9.
Bhandari N, Kale H, Carroll N, McAdam-Marx C, Ounpraseuth S, Tilford J, et al.
Urol Oncol
. 2022 Jun;
40(7):347.e17-347.e27.
PMID: 35643842
Objectives: To determine 1-year and 5-year total healthcare costs and healthcare resource (HRU) associated with renal cell carcinoma (RCC) in older Americans, from a healthcare sector perspective. Materials And Methods:...
10.
Parikh R, Hess L, Esterberg E, Bhandari N, Kaye J
Thyroid Res
. 2022 Feb;
15(1):2.
PMID: 35151352
Background: Medullary thyroid cancer (MTC) accounts for approximately 1.6% of new cases of thyroid cancer. The objective of this study was to describe patient characteristics, biomarker testing, treatment patterns, and...